Search Results
Your search for ,foR matches 32809 pages
Showing 7651 - 7700Fosnetupitant vs Fosaprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
In a Japanese phase III noninferiority trial (CONSOLE) reported in the Journal of Clinical Oncology, Hata et al found that fosnetupitant was noninferior to fosaprepitant in preventing nausea and vomiting in patients receiving highly emetogenic chemotherapy (both in combination with palonosetron and ...
Study Examines the Effect of Breast MRI on Short-Term Quality of Life in Women With DCIS
In a substudy of the ECOG-ACRIN E4112 cohort trial reported in JAMA Network Open, Fazeli et al found that approximately half of women with ductal carcinoma in situ (DCIS) undergoing magnetic resonance imaging (MRI) for pretreatment planning experienced fear or anxiety before and during the...
First-Line Ibrutinib/Rituximab in Patients With Mantle Cell Lymphoma Aged 65 and Older
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Jain et al found that chemotherapy-free treatment with the combination of ibrutinib and rituximab produced high overall and complete response rates in patients with previously untreated mantle cell lymphoma aged ≥...
COG AAML1331 Trial: Arsenic Trioxide and All-Trans Retinoic Acid in Pediatric Patients With APL
As reported in JAMA Oncology by Kutny et al, the Children’s Oncology Group (COG) AAML1331 trial has shown that treatment with arsenic trioxide and all-trans retinoic acid (ATRA) with no maintenance therapy produced high event-free and overall survival rates in pediatric patients with acute...
Immunomodulatory Effects of Neoadjuvant Nivolumab, Chemotherapy in NSCLC
The immunomodulatory effects of neoadjuvant immune-based treatments for non–small cell lung cancer (NSCLC) are becoming clearer, in part due to data presented by Schmidt et al at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting (Abstract 962). The first integrated analysis of...
Neoadjuvant Chemoradiation Plus Pembrolizumab Shows No Effect on Tumor-Infiltrating Lymphocytes in Pancreatic Cancer
The addition of the checkpoint inhibitor pembrolizumab to neoadjuvant chemoradiation has failed to overcome the immunosuppressive microenvironment of pancreatic cancer, according to data presented by Osama E. Rahma, MD, and colleagues at the Society for Immunotherapy of Cancer (SITC) 2021 Annual...
Eftilagimod Alpha Plus Paclitaxel May Improve Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer: AIPAC Trial
The addition of the LAG-3 protein eftilagimod alpha to paclitaxel led to a significant improvement in overall survival in younger patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, according to data presented by Hans Wildiers, MD, and colleagues at the Society for ...
Phase I Trial Investigates HER-Targeted CAR-M for HER2-Overexpressing Solid Tumors
HER2-targeted chimeric antigen receptor macrophages (CAR-M) could be the next cell therapies to treat advanced solid tumors overexpressing HER2, according to data presented by Kim A. Reiss, MD, and colleagues at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting (Abstract 951)....
FDA Approves Triplet Therapy for Previously Treated Patients With Relapsed or Refractory Multiple Myeloma
On November 30, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with carfilzomib (Kyprolis) plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of...
Aditya Bardia, MD, MPH, Comments on Findings From monarchE
The invited discussant of monarchE,1 Aditya Bardia, MD, MPH, Director, Breast Cancer Research, and Associate Professor of Medicine, Harvard Medical School, commented: “Based on a hazard ratio of 0.69 for invasive disease–free survival, the results are statistically significant and clinically...
Long-Term Follow-up of monarchE: Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer
Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy in the adjuvant treatment of early high-risk hormone receptor–positive, HER2-negative breast cancer, regardless of Ki67 index. The latest findings were reported at a ...
Can Antihistamines Influence Response to Immunotherapy?
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines was associated with improved responses to immune checkpoint inhibitors. The preclinical study, published by Li et al in Cancer Cell, demonstrated that the histamine receptor H1 (HRH1) acts...
High Response Rate With Venetoclax in Previously Treated Patients With Waldenström’s Macroglobulinemia
In a phase II study reported in the Journal of Clinical Oncology, Castillo et al found that venetoclax produced a high major response rate in previously treated patients with Waldenström’s macroglobulinemia. As stated by the investigators, “BCL2 is overexpressed and confers prosurvival signaling in ...
Cancer Incidence and Patterns in Individuals With Pathogenic/Likely Pathogenic Germline TP53 Variants
In an observational cohort study reported in The Lancet Oncology, de Andrade et al identified cancer incidence and patterns in individuals meeting criteria for Li-Fraumeni syndrome on the basis of presence of pathogenic or likely pathogenic germline TP53 variants. As stated by the investigators,...
Belzutifan Shows Activity in Patients With von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
In the phase II MK-6482-004 trial reported in The New England Journal of Medicine, Eric Jonasch, MD, and colleagues found that the hypoxia-inducible factor (HIF)-2α inhibitor belzutifan produced responses in patients with renal cell carcinoma (RCC) associated with von Hippel-Lindau disease....
Response to SARS–CoV-2 mRNA Vaccination in Patients With B-Cell Depletion Associated With CAR T-Cell Therapy
In a small single-institution study reported in a research letter in JAMA Oncology, Parvathaneni et al found that SARS–CoV-2 mRNA vaccination produced antibody responses in nearly half—and CD4 T-cell responses in more than half—of patients with B-cell depletion due to treatment with...
Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages
Kim A. Reiss, MD, of the University of Pennsylvania, discusses results of a phase I trial of a CAR-M engineered macrophage cancer therapy, known as CT-0508, for patients with solid tumors that overexpress HER2. CAR-M, designed to exploit the natural role of macrophages to initiate an antitumor...
Cancer-Related Financial Toxicity: Role of Race
In a study reported in JCO Oncology Practice, Panzone et al found that compared to White patients with a history of cancer, Black patients and ‘other race’ patients—but not Hispanic patients—were significantly more likely to have experienced financial toxicity due to cancer. Study Details The...
ALK Inhibition for Pediatric Patients With Advanced ALK-Positive Malignancies
In a phase I dose-escalation and dose-expansion study reported in The Lancet Oncology, Fischer et al found that the ALK inhibitor ceritinib produced durable responses in pediatric patients with relapsed or refractory, locally advanced or metastatic ALK-positive malignancies. Study Details In the...
Does Yoga Improve Quality of Life in Men With Prostate Cancer?
A diagnosis of prostate cancer may translate to approximately a 30% increase in the incidence of depression and anxiety, a fourfold higher risk of heart attack, and a twofold higher risk of suicide. A study published by Kaushik et al in Prostate Cancer and Prostatic Diseases aimed to evaluate the...
Expert Point of View: Charles L. Shapiro, MD
Charles L. Shapiro, MD, Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, commented on the findings of the coopERA trial for The ASCO Post. He maintained that the oral selective estrogen receptor degraders now in development will be a...
Phase II Breast Cancer Trial: Large Declines in Ki67 Index Seen With Oral Selective Estrogen Receptor Degrader
In the phase II coopERA Breast Cancer trial, which evaluated two endocrine neoadjuvant therapies in estrogen receptor–positive, HER2-negative early breast cancer, the oral selective estrogen receptor degrader giredestrant led to a greater reduction in Ki67 level—a measure of cancer cell...
FDA Approves Pafolacianine to Help Identify Ovarian Cancer Lesions
On November 29, the U.S. Food and Drug Administration (FDA) approved pafolacianine (Cytalux), a targeted fluorescent imaging agent intended to assist surgeons in identifying ovarian cancer lesions. The drug, which is indicated for use in adult patients with ovarian cancer and is administered in the ...
Impact of Prior Blinatumomab Exposure on CD19-Targeted CAR T-Cell Therapy Outcomes in Pediatric Patients With B-Cell ALL
In a study reported in the Journal of Clinical Oncology, Myers et al found that lack of response to prior blinatumomab treatment was associated with poorer outcomes with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy (CD19-CAR) in children and young adults with relapsed or refractory...
Research Assesses Molecular Hallmarks of Moles and Melanomas
Moles and melanomas both originate from the same type of cell—melanocytes. A study published by McNeal et al in eLife Magazine aimed to explain how common moles and melanomas form and why moles can subsequently change into melanoma. Melanocytes are cells that give color to the skin to protect it...
Addressing the Global Challenges of Cancer Prevention and Treatment
Nearly 20 million people around the world were diagnosed with cancer in 2020, with 10 million losing their lives to this devastating disease. We highlight here the salient points from our article published in CA: A Cancer Journal for Clinicians,1 which describes the major themes and...
Study Examines Treatment-Related Regret Among Men With Localized Prostate Cancer
In a prospective cohort study (CEASAR) reported in JAMA Oncology, Wallis et al found that patient expectations of treatment efficacy and adverse effects were associated with treatment-related regret at 5 years after diagnosis in men with localized prostate cancer. As stated by the investigators,...
Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Patients With Metastatic Melanoma
In a single-institution study reported in The Lancet Oncology, Qian et al found that the administration of immune checkpoint inhibitors after 4:30 PM was associated with poorer overall survival vs infusion earlier in the day in patients with metastatic melanoma. As stated by the investigators, “The ...
Research Letter Examines Changes in Cancer Mortality 50 Years After Passage of the National Cancer Act
In a study reported in a research letter in JAMA Oncology, Kratzer et al found that mortality from cancer overall has decreased significantly since the passage of the National Cancer Act in 1971, with reductions observed in 12 of the 15 cancer sites associated with the highest mortality rates in...
FDA Approves Maribavir for Posttransplant CMV
On November 23, the U.S. Food and Drug Administration (FDA) approved the antiviral maribavir (Livtencity) for adult and pediatric patients aged 12 years and older (and weighing at least 35 kg) with posttransplant cytomegalovirus (CMV) infection or disease that is not responsive (with or without...
SARC Appoints Jonathan Fletcher, MD, to New Role of Chief Scientific Officer
Sarcoma Alliance for Research Through Collaboration (SARC) recently announced the appointment of Jonathan Fletcher, MD, as Chief Scientific Officer (CSO). This is a new role at the nonprofit cancer research organization, a leader in collaborative discovery, translational research, and clinical...
New Breast Cancer Survivorship Program Launched by USC Norris Comprehensive Cancer Center
There are currently more than 3.8 million breast cancer survivors living in the United States, and 3 out of 10 women with invasive breast cancer will develop metastases. However, if some breast cancer cells remain after treatment, the amount is often too small to be detected by mammograms or...
Eric P. Winer, MD, FASCO, to Lead Yale Cancer Center and Smilow Cancer Hospital
After an extensive national search, Yale School of Medicine and Yale New Haven Health have announced that Eric P. Winer, MD, FASCO, will be the next Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven, effective February 1, 2022. Nita Ahuja, MD, MBA,...
Possible Impact of Nurse Navigation Program in Achieving Equitable Care and Outcomes in Minority vs White Patients
In a single-institution study reported in Cancer, Bei Hu, MD, of the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health in Charlotte, and colleagues found that use of a dedicated nurse navigation program contributed to redressing the recognized inequities...
American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact Award
The American Cancer Society (ACS) and Flatiron Health recently presented the 2021 Real-World Data Impact Awards, which will support research into health disparities among patients with advanced pancreatic and breast cancers. This year marks the third year of the joint grant-making program, under...
Shiitake Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on shiitake mushroom ...
Passionate About Surgical Oncology, Masakazu Toi, MD, PhD, Is a Leader in Japanese Clinical Trials
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Masakazu Toi, MD, PhD, a clinical breast cancer expert who is keen on research that translates basic science into clinical study. He is involved in various innovative research projects on the development ...
Maintenance Daratumumab After Initial Therapy for Transplant-Eligible Multiple Myeloma: More Questions Than Answers From CASSIOPEIA Part 2
Bortezomib, thalidomide, and dexamethasone (VTd) is an acceptable, effective standard-of-care induction treatment in Europe for patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantation. CASSIOPEIA is a two-part, open-label, randomized, phase III trial in...
Maintenance Daratumumab Prolongs Progression-Free Survival in Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Philippe Moreau, MD, of the University Hospital Hôtel-Dieu, Nantes, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has showed significantly prolonged progression-free survival with maintenance daratumumab vs observation...
Tools for High-Quality, Accessible Care
Tools that make it easier for patients to access care and for their physicians to monitor their health status have also emerged with the advent of digital resources. In the closing panel of the NCCN Policy Summit, participants described tools developed by their own organizations to improve quality...
The Promise and the Challenge: Experts and Innovators Explore the Impact of New Technologies in Cancer Care
Artificial intelligence, digital therapeutics, telehealth, biometric monitoring: the terms alone are enough to suggest that cancer care is entering a new age, one characterized by tools and practices based on technologic innovation. To explore the impact of these new tools, the National...
The Role of Spirituality in Palliative Care
National surveys consistently show that spirituality and religion are important components in the lives of most Americans, with more than 90% of adults expressing a belief in God and more than 70% identifying religion as one of the most important influences in their lives.1 Studies also show that...
Five Percent Overall Medicare Reimbursement Cut Estimated for Medical Oncology in 2022
On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the 2022 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) final rule. Although ASCO will analyze the rule in greater detail in the coming days, initial highlights from the rule are outlined...
Mortality Risk in Patients With Cancer and SARS–CoV-2 Higher Among Older Patients With B-Cell Malignancies and Those Who Previously or Currently Smoke
A recent study published in JCO Oncology Practice found that patients with certain cancers have a higher mortality risk than those with other cancer types if they have contracted the novel coronavirus (SARS–CoV-2).1 Specifically, older patients with B-cell malignancies who acquire SARS–CoV-2 who...
COVID-19 Resources for People With Cancer
ASCO has compiled a number of resources to help people with cancer navigate COVID-19. Coronavirus and COVID-19: What People With Cancer Need to Know Cases of COVID-19 have arisen all over the world. Here’s what people with cancer and cancer survivors need to know about the disease. Available at...
Northwell Names Fidel Valea, MD, to Leadership Roles in Gynecologic Oncology
Fidel Valea, MD, recently announced his appointment as System Chief of Gynecologic Oncology at Northwell Health and Director of Gynecologic Oncology at the Northwell Health Cancer Institute. He will see patients in New Hyde Park, New York, and Manhattan. In his role as System Chief of Gynecologic...
Craig Sauter, MD, Joins Cleveland Clinic
Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at the Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, recently announced the appointment of Craig Sauter, MD, as the new Director of Blood and Marrow Transplant Program at the Cleveland...
MSK Appoints Saad Z. Usmani, MD, MBA, FACP, Chief of Myeloma Service
Physician leader and clinical and translational investigator Saad Z. Usmani, MD, MBA, FACP, recently joined Memorial Sloan Kettering Cancer Center (MSK) as Chief of Myeloma Service. He was also appointed Professor at the Joan & Sanford I. Weill Medical College of Cornell University. Dr....
Purdue Center for Cancer Research Receives $1.5 Million for Endowed Professorship
The Henry E. Haller Jr. Foundation and the Walther Cancer Foundation together will donate a total of $1.5 million to the Purdue Center for Cancer Research and the College of Science in Cancer Biology in West Layfayette, Indiana. A donation of $750,000 from the Henry E. Haller Jr. Foundation was...
Duration of Endocrine Therapy in Breast Cancer: How Much of a Good Thing Is Too Much?
Estrogen receptor–positive breast cancer is the most common type of breast cancer, diagnosed in more than 2.3 million women around the world each year, including more than 200,000 in the United States alone. Adjuvant endocrine therapy is a mainstay of treatment for these millions of women and is a...
